Read + Share
Zhou Q, Xu CR, Cheng Y, Liu YP, et al. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated,
advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Cancer Cell 2021;39:1279-1291.
PMID: 34388377
|
 |
|
Zhou Q, Xu CR, Cheng Y, Liu YP, et al. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated,
advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Cancer Cell 2021;39:1279-1291.
PMID: 34388377
|
|
|
|